- Home
- ENTA vs GPRK Comparison
ENTA vs GPRK Comparison
Compare ENTA & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENTA | GPRK |
|---|---|---|
| Founded | 1995 | 2002 |
| Country | United States | Colombia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.6M | 608.0M |
| IPO Year | 2012 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ENTA | GPRK |
|---|---|---|
| Price | $14.43 | $9.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $20.40 | $8.50 |
| AVG Volume (30 Days) | 111.5K | ★ 1.4M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.21% |
| EPS Growth | ★ 29.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,814,000.00 | N/A |
| Revenue This Year | $7.76 | $39.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.70 |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $4.83 | $5.75 |
| 52 Week High | $17.15 | $10.34 |
Technical Indicators
Market Signals| Indicator | ENTA | GPRK |
|---|---|---|
| Relative Strength Index (RSI) | 64.54 | 52.10 |
| Support Level | $13.39 | $7.96 |
| Resistance Level | $15.52 | $10.16 |
| Average True Range (ATR) | 0.82 | 0.56 |
| MACD | 0.24 | 0.02 |
| Stochastic Oscillator | 89.49 | 58.05 |
Price Performance
Historical ComparisonAbout ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
About GPRK Geopark Ltd
GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.